Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Operating Expenses (2021 - 2025)

Krystal Biotech's Operating Expenses history spans 5 years, with the latest figure at $62.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 25.93% year-over-year to $62.7 million; the TTM value through Dec 2025 reached $227.8 million, up 1.36%, while the annual FY2025 figure was $227.8 million, 1.36% up from the prior year.
  • Operating Expenses for Q4 2025 was $62.7 million at Krystal Biotech, up from $56.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $62.7 million in Q4 2025 and bottomed at $14.4 million in Q1 2021.
  • The 5-year median for Operating Expenses is $43.9 million (2023), against an average of $41.3 million.
  • The largest annual shift saw Operating Expenses surged 249.91% in 2022 before it decreased 8.07% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $21.9 million in 2021, then skyrocketed by 58.94% to $34.8 million in 2022, then increased by 11.86% to $38.9 million in 2023, then increased by 27.94% to $49.8 million in 2024, then rose by 25.93% to $62.7 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Operating Expenses are $62.7 million (Q4 2025), $56.4 million (Q3 2025), and $56.7 million (Q2 2025).